BioMarin Announces Acquisition of Alesta Therapeutics for $275M Upfront

What Happened

• BioMarin Pharmaceutical Inc. announced on August 17–18, 2026 that it entered into a Share Purchase Agreement to acquire Alesta Therapeutics B.V., a Netherlands-based developer of oral small-molecule therapies for underserved rare diseases.
• The deal calls for $275 million in upfront cash (subject to customary post-closing purchase price adjustment) and up to $215 million in contingent, development-based milestone payments. The transaction is cash‑free, debt‑free and is expected to close in Q3 2026, subject to customary closing conditions and a pre-closing transfer of certain Alesta assets to Anaheim SpinCo B.V. A press release was issued August 18, 2026 (filed as Exhibit 99.1).

Key Details

• Purchase Agreement executed: August 17, 2026; press release: August 18, 2026.
• Upfront consideration: $275 million in cash (customary post-closing adjustment).
• Contingent payments: up to $215 million tied to development milestones.
• Closing conditions include absence of injunctions, completion of asset transfer to SpinCo, and other customary conditions.

Why It Matters

• The acquisition adds Alesta’s early-stage oral small‑molecule programs to BioMarin’s pipeline, potentially expanding its rare‑disease portfolio.
• Financially, the immediate cash outlay is $275M (plus adjustment), with additional potential payments up to $215M only if milestones are achieved — investors should note the contingent nature of a meaningful portion of the purchase price.
• The transaction is subject to closing conditions and integration execution; BioMarin’s filings include standard forward‑looking disclaimers and risk factors that could affect timing, costs, or expected benefits.